Section
Myeloid cell CD36 deficiency reduces hepatic fibrosis by preventing macrophage ferroptosis and restoring antigen presentation, thereby enhancing CD8+ T cell-mediated adaptive immunity. This identifies CD36 as a promising therapeutic target
This exploratory study evaluates the safety and efficacy of blinatumomab in treating dermatomyositis and refractory ANCA-associated vasculitis, revealing promising immunological and clinical improvements without serious adverse events over
This study reveals a distinctive dual Th17/Th2 immune endotype and pronounced IL-36 activation in Taiwanese patients with psoriasis, highlighting the need for tailored therapeutic approaches in this ethnic group.
A first-in-human study demonstrates that BCMA-targeted CAR T-cell therapy induces rapid, sustained platelet recovery and durable drug-free remission in refractory primary immune thrombocytopenia with manageable safety.
This review synthesizes current pediatric data on dupilumab for eosinophilic esophagitis, highlighting high remission rates, treatment deescalation, and safety, supported by mechanistic and clinical trial evidence.
This article reviews a pediatric emergency department initiative that increased optimal antibiotic prescribing for community-acquired pneumonia and acute bacterial rhinosinusitis, improving adherence to updated short-course guidelines and m
Reduced expression of splicing factor SRSF1 disrupts LCK exon 8 inclusion, impairing TCR signaling and regulatory T-cell induction, thereby contributing to immune dysregulation in immune thrombocytopenia.
A 9-year-old girl with atopic dermatitis and relapsing nephrotic syndrome achieved sustained remission of both conditions after dupilumab therapy, enabling withdrawal of steroids and tacrolimus.
Autoimmune neutropenia (AiN) in adults, though rare, is a chronic condition predominantly affecting women with autoimmune comorbidities. Treatment prioritizes observation, with therapies aimed at boosting neutrophil counts or modulating imm
This study reveals that dual BAFF-APRIL blockade with telitacicept distinctly remodels pathogenic autoantibodies in antiphospholipid syndrome, showing differential effects across immunoglobulin isotypes and identifying marrow plasma-cell cl
This article explores distinct immune cell activations in ACPA-positive individuals progressing to rheumatoid arthritis, emphasizing type I interferon activity prior to ultrasound-detectable synovitis and subsequent inflammatory shifts mark
Interim analysis of a phase 3 trial demonstrates povetacicept’s efficacy in reducing proteinuria and pathological markers in IgA nephropathy, with a favorable safety profile.
This review synthesizes phase 3 RAPIDe-3 trial results demonstrating oral deucrictibant’s rapid efficacy and safety for hereditary angioedema attacks, contextualized with phase 2 studies and prophylactic applications, highlighting its
In a phase 2 trial, oral QY201 significantly improved skin outcomes in moderate-to-severe atopic dermatitis with favorable safety, supporting further phase 3 evaluation.
This study reveals that familial hypercholesterolaemia accelerates thymic ageing, reducing thymic output and altering T-cell diversity; statin therapy partially preserves thymic function, suggesting integrated metabolic-immunologic manageme
Ivarmacitinib, a selective JAK1 inhibitor, demonstrated rapid efficacy and immune remodeling in palmoplantar pustulosis over 12 weeks, with favorable safety and potential biomarkers for response stratification.
The AMETHYST Phase 2 trial demonstrated that litifilimab significantly improves skin symptoms in cutaneous lupus erythematosus with a favorable safety profile, marking a potential new targeted treatment for this challenging condition.
In EGPA patients unresponsive to mepolizumab, switching to benralizumab improves lung function, reduces glucocorticoid use, and shows a favorable safety profile, suggesting its potential as an effective alternative treatment.
This study uncovers how HSP70-driven inflammatory interactions between macrophages and stromal cells disrupt the endometrial environment, contributing to recurrent implantation failure by impairing decidualization and immune homeostasis.
This phase 2b trial demonstrates that oral icotrokinra, targeting the interleukin-23 receptor, significantly improves clinical outcomes in moderate to severe ulcerative colitis compared to placebo.
